What You Should Know:
– Plexāā, a pioneering UK-based MedTech startup behind the award-winning BLOOM⁴³ medical device for breast surgery closes $4.5M funding extension round led by TCP Health Ventures. The extension round includes both existing and new investors, including TCP. Further investment comprises over $1.6M in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3M from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech.
– The strategic capital infusion will support the imminent U.S. launch of BLOOM⁴³, lay the groundwork for future innovations, and strengthen the company’s position ahead of its planned Series A fundraising round.
Breast Cancer Surgical Readiness with Supraphysiological Preconditioning™
Complication rates in breast surgeries, which can include infection, skin necrosis, and the need for additional surgeries, have been recorded as high as 30 percent. BLOOM⁴³ is the world’s first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning™. This new technique safely and intermittently thermally preconditions the skin, causing the release of heat-shock proteins that lead to vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials.
Along with its BLOOM⁴³ companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, leveraging the power of holistic Prehabilitation™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch.
Expansion Plans
Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery and to deliver transformative solutions that address unmet needs in surgical care. The company is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes.
